RxDoctor Payments Data

Lisa Boyd, PA

Physician Assistant · Dallas, NCNPI 1427098987

Payments from drug & device makers

$2,052in general payments, 2019–2025

Across 26 payments — averaging $78.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$597
  • Exact Sciences$407
  • Johnson & Johnson$241
  • Phathom Pharmaceuticals, Inc.$204
  • GSK$119
  • E.r. Squibb & Sons, L.L.C.$106
  • plus $379 from 4 others

What the payments were for

  • Food & beverage$2,052100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,052 in reported general payments places this provider in the 80th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$37,151
Medicare patients
120
Services billed
466

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin30$34,413
EliquisApixaban33$27,799
FarxigaDapagliflozin Propanediol28$24,093
XareltoRivaroxaban18$20,619
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$13,235
SymbicortBudesonide/Formoterol Fumarate27$5,993
Breo ElliptaFluticasone/Vilanterol13$5,289
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$4,242
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$2,651
Atorvastatin Calcium289$2,114
Albuterol Sulfate HfaAlbuterol Sulfate87$1,887
Mometasone Furoate20$1,864
Omeprazole126$1,503
Gabapentin115$1,474
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic23$1,367

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$597$30,08755 claims
Johnson & JohnsonXarelto$241$20,61918 claims
GSKTrelegy Ellipta, Breo Ellipta$119$18,52426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Dallas

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →